Drug use is a reality in New Zealand — and the harms from drug use (overdose, infection, family breakdown, violence, crime) affect not just people who use drugs but their families and communities. Harm reduction approaches — meeting people where they are, reducing risk without requiring abstinence — are increasingly central to New Zealand's drug policy. Understanding the funding landscape matters for harm reduction organisations, addiction services, communities, and funders committed to reducing drug-related harm.
Scale
Who is affected
Drug harm is concentrated among:
- People with co-occurring mental health conditions
- People experiencing homelessness
- Māori (particularly methamphetamine harm)
- Young people
- People who have experienced trauma
- People in justice settings (high rates of drug use in prison populations)
The harm reduction philosophy
Harm reduction accepts that drug use occurs — and focuses on reducing harm rather than requiring abstinence:
- Needle exchange reduces HIV and hepatitis C transmission
- Drug checking services reduce overdose from contaminated drugs
- Opioid agonist therapy reduces crime, disease, and death
- Naloxone distribution prevents overdose death
- Peer support reduces isolation and increases help-seeking
Ministry of Health / Health NZ
The primary funder of drug harm reduction services:
- Opioid Agonist Treatment (OAT) — methadone and buprenorphine programmes
- Alcohol and Drug (AOD) treatment services (contracted)
- Needle exchange programme (NZAF and partner agencies)
- Drug checking services (partially funded)
- Community harm reduction initiatives
Ministry of Justice
Justice funds some drug-related programmes at the intersection of offending:
- Drug courts
- Community sentences with drug treatment conditions
ACC
ACC funds treatment for injury-related conditions that intersect with drug use.
The New Zealand Needle Exchange Programme is one of the oldest and most established harm reduction services:
- New Zealand AIDS Foundation (NZAF) coordinates nationally
- Pharmacy-based distribution (thousands of exchange sites)
- Satellite needle exchange programmes
- Needles, syringes, and safer use equipment
- HIV and hepatitis C testing
- Linkage to treatment
Funding: Government contracts, NZAF fundraising, some gaming trust and Lotteries support.
OAT (methadone, buprenorphine/naloxone) dramatically reduces opioid overdose death, crime, and HIV transmission:
- Publicly funded through Health NZ
- Delivered through specialist addiction services and some community pharmacies
- Waitlists exist in some regions — a significant gap
- Expanding access through primary care is a priority
New Zealand has led the world in drug checking:
- The Drug Foundation of New Zealand operates drug checking services
- Drug Analysis Response & Testing (DART)
- Tests substances for unexpected adulterants (fentanyl, other dangerous drugs)
- Brief intervention at point of check
- Legal since 2021 (Drug and Substance Checking Legislation Act)
Drug checking services are partially government-funded, with gaps filled by philanthropy and fundraising.
New Zealand Drug Foundation
The Drug Foundation is the peak drug policy and harm reduction organisation:
- Policy advocacy (drug law reform, harm reduction)
- Drug checking services
- Research and information
- Education programmes
- Partly philanthropically funded
Needle Exchange Programme (NZAF)
Needle and syringe programme reducing bloodborne virus transmission — primarily government contracted.
Odyssey (Auckland) and regional AOD providers
Community-based alcohol and drug treatment and harm reduction — government contracted, some philanthropic support.
Te Ara Tūhono (Māori AOD services)
Kaupapa Māori approaches to addiction support — meeting Māori where they are.
Methamphetamine (meth/P) causes severe harm — psychosis, family violence, child neglect, crime. New Zealand has elevated methamphetamine use rates:
Funded approaches
- Methamphetamine-specific residential treatment
- Family harm response (including meth-related family violence)
- Māori and Pacific meth harm reduction
- Rural community meth response
- Parenting and child safety where meth is a factor
Peer support
People with lived experience supporting others:
- Peer-delivered harm reduction (needle exchange peers, drug checking peers)
- Recovery peer support
- Peer-run drop-in centres
Community outreach
Reaching people who won't access traditional services:
- Mobile needle exchange
- Outreach to sex workers
- Outreach in rural communities
- Festival and event outreach
Naloxone distribution
Naloxone reverses opioid overdose — community distribution saves lives:
- Take-home naloxone programmes
- Peer training in overdose response
- Community pharmacy naloxone access
Diversion and Justice-linked
Diverting drug users from prison to treatment:
- Police diversion programmes
- Drug court support
- Community detention alternatives
Harm reduction framing
Not all funders are comfortable with harm reduction philosophy — particularly gaming trusts and more conservative philanthropic funders. Know your funder's values. Health-focused funders (Ministry of Health, health foundations) are more aligned with harm reduction. Frame accordingly.
Non-judgmental approach
Harm reduction requires non-judgmental service delivery — demonstrate this in how you describe participants (people who use drugs, not addicts).
Lived experience leadership
Harm reduction is most effective when people with lived experience lead it. Show peer leadership in governance and delivery.
Overdose prevention evidence
The evidence for harm reduction is strong — needle exchange, OAT, naloxone, drug checking all have compelling international evidence. Reference it. The evidence for abstinence-only approaches for many drug types is much weaker — be honest about the evidence base.
Cultural safety
Drug harm reduction for Māori and Pacific communities must be culturally safe — not a Western biomedical approach imposed on communities with different relationships to healing and community.
Tahua's grants management platform supports health funders and drug harm reduction organisations — with programme participant tracking, outcome measurement, community reach data, and the tools that help harm reduction funders demonstrate impact in reducing New Zealand's drug-related burden.